307 Westlake Avenue North
About Juno Therapeutics
Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.
The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments have the potential to reduce longer-term toxicities associated with chemotherapeutics. Our goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure. Each product candidate has the potential to treat a variety of high-risk cancers.
August 5, 2013
Founders: : Hans Bishop, Richard Klausner, and Robert Nelsen
CEO and Co-founder: Hans Bishop
Please click here for job opportunities.
Please click here for clinical trial information.
Tweets by Juno
228 articles with Juno Therapeutics
Celgene is eying the first quarter of 2019 to submit a second New Drug Application (NDA) for multiple sclerosis treatment ozanimod.
While the biopharma industry awaits news of an acquisition of Shire by Takeda Pharmaceuticals, it’s a good time to take a look back at the bigger deals so far this year.
A nonprofit organization, Knowledge Ecology International (KEI), recently filed a lawsuit against the National Institutes of Health (NIH) over Gilead Sciences’ patents for a new chimeric antigen receptor T-cell (CAR-T) therapy.
It’s no secret that China has become an ever-increasing important component for drug development. Not only is the country seen as a lucrative market for drugs, entities within the country are making heavy investments in the global biotech industry.
Scott Smith, Celgene’s chief operating officer, abruptly resigned Monday. His decision to leave appears to be prompted by a restructuring of the company’s executive team.
3/15/2018Celgene has a deep pipeline and a $69 billion market cap, but it could consider going private in 2019 via a leveraged buyout.
JW Therapeutics, a clinical stage biopharma company founded by Juno Therapeutics and WuXi AppTec Group, has closed a Series A financing worth $90 million.
While the focus has been on M&A activity, Venture Capital firms have been investing billions in Biotech companies in 2018.
Celgene Completes Acquisition of Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy
Advances strategy to become a leader in global cellular immunotherapy.
Celgene Corporation (NASDAQ:CELG) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Juno Therapeutics, Inc. at a price of $87.00 per share, net to the seller in cash, without interest and less required withholding taxes, expired at 12:00 midnight ET, at the end of the day on Friday, March 2, 2018.
The U.S. Food and Drug Administration stunned the company with a Refusal to File letter regarding its New Drug Application (NDA) for multiple sclerosis treatment ozanimod.
The passing of tax reform led most analysts to predict that 2018 will be a strong year for mergers and acquisitions.
Juno's Hans Bishop will take home $287M after Celgene acquired his company.
The tender offer is being made in connection with the Agreement and Plan of Merger, dated January 21, 2018, by and among Celgene, Blue Magpie Corporation and Juno.
Employees of Juno received a surprise in their Monday morning emails.
The announcement sent shares of Juno soaring more than 27 percent in pre-market trading to $86.26.
Investors and analysts have given it some thought and mostly think it's a sensible acquisition.
1/17/2018We are still only in January and Celgene and Sanofi have already made a combined $20B in M&A deals.
1/17/2018The rumors have caused Juno's stock to rocket more than 50 percent to $68.80 in premarket trading.
Under her leadership, Genentech became the first biotech company to implement several key technology platforms at scale, and her teams consistently provided exceptional user experience to over 44,000 people.